← All indications
Granuloma
A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.
Subtype terms (10)
More specific conditions that are subtypes of Granuloma in the MeSH hierarchy.
- Angiolymphoid Hyperplasia with Eosinophilia
- Churg-Strauss Syndrome
17 drugs (15 approved, 2 experimental)
- Eosinophilic Granuloma
11 drugs (9 approved, 2 experimental)
- Granuloma Annulare
4 drugs approved
- Granuloma, Foreign-Body
- Granuloma, Giant Cell
1 drug approved
- Granuloma, Plasma Cell
- Granuloma, Pyogenic
1 drug approved
- Granuloma, Respiratory Tract
- Necrobiotic Xanthogranuloma
Drugs by status
Phase 4 trials (4)
Phase 3 trials (6)
Phase 2 trials (22)
- 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
- plerixafor
- busulfan
- cd3,cd19 depleted hematopoietic stem cells
- ibuprofen
- eltrombopag
- ifx-1
- Filgrastim
- palifermin
- rimabotulinumtoxinB
- calcitonin salmon
- sirolimus
- silver nitrate
- bevacizumab
- cetuximab
- tocilizumab
- pcclchimgp91s lentiviral vector transduced cd34+ cells
- erlotinib
- sargramostim
- omeprazole
- fludeoxyglucose f-18
- base-edited hematopoietic stem and progenitor cells
Phase 1 trials (10)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (23)
- Amgen
- Genethon
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- National Cancer Institute (NCI)
- Baylor University
- University of London
- Harvard University
- Radboud University
- Seoul National University
- Stanford University
- University of Tehran
- University of Zurich
- University of California, Los Angeles
- University of Copenhagen
- Leiden University
- University of Texas at Houston
- University of Paris
- J. W. Goethe University
- University of Texas, San Antonio
- California Institute for Regenerative Medicine
- German Federal Ministry of Education and Research
- ViroMed
- Shaheed Zulfiqar Ali Bhutto Medical University
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (6)